Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Pfizer (PFE – Research Report), with a price target ...

The latest trading session saw Pfizer (PFE) ending at $24.70, denoting a +0.65% adjustment from its last day's close. This change lagged the S&P 500's 0.67% gain on the day. Meanwhile, the Dow ...

Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation at its ...

(Reuters) -Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation ...

Pfizer's latest plot twist includes an expanded European nod for its RSV vaccine, ABRYSVO, and a new autoimmune collab with ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

At present, Healthcare’s dividend yield is 7.3% at 31 cents per share. Over a year, HR stock is up nearly 20%, effectively ...

Pfizer’s stock has underperformed lately, falling 4.6% while still doing marginally better than its peers. Analysts have made ...

Dziubinski: All right, we’ve arrived at everyone’s favorite part of the show: this week’s stock picks. Now these three stocks ...

Vaccine stocks are down after the health agency's top immunization official announced the move Monday, citing Secretary ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...